Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity.

× No keyword cloud information.

24 in total

1. Leukemia regression by vascular disruption and antiangiogenic therapy.

Authors: Gerard J Madlambayan; Amy M Meacham; Koji Hosaka; Saad Mir; Marda Jorgensen; Edward W Scott; Dietmar W Siemann; Christopher R Cogle
Journal: Blood Date: 2010-05-14 Impact factor: 22.113

2. Myeloid malignancies and the microenvironment.

Authors: Claudia Korn; Simón Méndez-Ferrer
Journal: Blood Date: 2016-11-15 Impact factor: 22.113

3. FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia.

Authors: Preetesh Jain; Hun Ju Lee; Wei Qiao; William Wierda; Ohad Benjamini; Jan Burger; Alessandra Ferrajoli; Zeev Estrov; Hagop Kantarjian; Michael Keating; Susan O'Brien
Journal: Cancer Date: 2014-07-15 Impact factor: 6.860

4. Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance.

Authors: Qing-feng Xiang; Fang Wang; Xiao-dong Su; Yong-ju Liang; Li-sheng Zheng; Yan-jun Mi; Wei-qiang Chen; Li-wu Fu
Journal: Cell Oncol (Dordr) Date: 2011-01-28 Impact factor: 6.730

5. PI3-kinase inhibition as a strategy to suppress the leukemic stem cell niche in Ph+ chronic myeloid leukemia.

Authors: Yüksel Filik; Karin Bauer; Emir Hadzijusufovic; Patrick Haider; Georg Greiner; Nadine Witzeneder; Gregor Hoermann; Philipp J Hohensinner; Karoline V Gleixner; Johann Wojta; Wolfgang R Sperr; Peter Valent
Journal: Am J Cancer Res Date: 2021-12-15 Impact factor: 6.166

6. High-grade glioma before and after treatment with radiation and Avastin: initial observations.

Authors: Ingeborg Fischer; Clare H Cunliffe; Robert J Bollo; Shahzad Raza; David Monoky; Luis Chiriboga; Erik C Parker; John G Golfinos; Patrick J Kelly; Edmond A Knopp; Michael L Gruber; David Zagzag; Ashwatha Narayana
Journal: Neuro Oncol Date: 2008-08-12 Impact factor: 12.300

Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity.

1. Leukemia regression by vascular disruption and antiangiogenic therapy.

2. Myeloid malignancies and the microenvironment.

3. FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia.

4. Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance.

5. PI3-kinase inhibition as a strategy to suppress the leukemic stem cell niche in Ph+ chronic myeloid leukemia.

6. High-grade glioma before and after treatment with radiation and Avastin: initial observations.

Review 7. Vascular endothelial growth factor signaling in acute myeloid leukemia.

Review 8. Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.

9. Clinical trials with anti-angiogenic agents in hematological malignancies.

10. Angiogenesis in acute myeloid leukemia and opportunities for novel therapies.